Sumitomo Pharma Co., Ltd.
SMDPY · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.10 | -0.00 | 0.02 | 19.97 |
| FCF Yield | 1.31% | -164.47% | -0.24% | 4.55% |
| EV / EBITDA | 9.64 | -1.94 | -155.69 | 3.79 |
| Quality | ||||
| ROIC | 7.05% | -50.67% | -18.12% | 2.78% |
| Gross Margin | 61.53% | 59.76% | 67.79% | 71.94% |
| Cash Conversion Ratio | 0.70 | 0.77 | -0.12 | 0.77 |
| Growth | ||||
| Revenue 3-Year CAGR | -10.46% | -17.49% | 2.50% | 5.08% |
| Free Cash Flow Growth | 101.35% | -31,902.86% | -104.54% | -85.78% |
| Safety | ||||
| Net Debt / EBITDA | 4.98 | -1.39 | -58.00 | 0.66 |
| Interest Coverage | 2.13 | -82.81 | -24.37 | 19.75 |
| Efficiency | ||||
| Inventory Turnover | 1.63 | 1.10 | 1.90 | 1.59 |
| Cash Conversion Cycle | 200.94 | 315.50 | 228.26 | 276.54 |